微小RNA-182在系统性红斑狼疮中的诊断价值
| 作者: |
1余伟,
2徐蔷薇,
2季蓉,
1黄红宇,
2任天丽
1 无锡市第二人民医院检验科，江苏 无锡 214002 2 无锡市第二人民医院风湿免疫科，江苏 无锡 214002 |
| 通讯: | |
| DOI: | 10.3978/j.issn.2095-6959.2017.03.017 |
| 基金: | 无锡市医院管理中心医学科技项目, YGZXQ1301 |
摘要
目的：观察microRNA-182在系统性红斑狼疮(systemic lupus erythematosus，SLE)患者外周血的表达水平，明确microRNA-182应用于SLE诊断的临床价值。方法：选取2014年1月至2015年1月在南京医科大学附属无锡市第二人民医院就诊的SLE患者80例(SLE组)，同期招募健康体检者70例(对照组)。2组患者入院即刻抽取约5 mL静脉血，采用TaqMan real-time PCR方法测定所有受试者外周血microRNA-182表达水平。根据SLE患者是否首次发病，分为初发SLE亚组及非初发SLE亚组，并比较两亚组患者microRNA-182表达水平的差异。分析microRNA-182水平与抗ds-DNA抗体及SLE疾病活动度指数(systemic lupus erythematosus disease activity index，SLEDAI)的相关性。结果：SLE患者外周血中microRNA-182水平较健康对照组显著升高(1.58±0.69 vs. 0.40±0.35，P<0.01)，其中初发SLE患者microRNA-182水平较非初发SLE患者显著升高(2.05±0.56 vs. 1.10±0.45，P<0.01)，同时发现microRNA-182水平与SLEDAI(r=0.466，P<0.01)及抗ds-DNA抗体(r=0.442，P<0.01)具有显著相关性。同时，ROC曲线发现microRNA-182在诊断SLE方面具有较高价值[AUC：0.94(95% CI 0.91~0.98)]。结论：microRNA-182可以作为诊断及SLE的生物标志物。
关键词：
微小RNA-182
系统性红斑狼疮
抗ds-DNA抗体
SLE疾病活动度指数
Value of microRNA-182 in diagnosis and prediction for systemic lupus erythematosus
DOI: 10.3978/j.issn.2095-6959.2017.03.017
Abstract
Objective: To study the expression of microRNA-182 in systemic lupus erythematosus (SLE) for exploring the value of diagnosis for SLE. Methods: Eighty SLE patients served as a SLE group and 70 healthy volunteers as a healthy control (HC) group from Wuxi Second People’s Hospital of Nanjing Medical University between January 2014 and January 2015. About 5 mL venous blood was collected from all subjects on admission, and the levels of microRNA-182 were detected by TaqMan real-time (RT) PCR. Meanwhile, SLE patients were divided into a newly diagnosed subgroup (n=40) and a non-newly diagnosed subgroup (n=40), the difference of expression microRNA-182 were compared in the two subgroups. The relationship between microRNA-182 levels and anti-ds-DNA antibody and SLEDAI were explored subsequently. Results: The levels of microRNA-182 in the SLE group were significantly higher than the HC group (1.58±0.69 vs. 0.40±0.35, P<0.01), meanwhile its levels in newly diagnosed subgroup were significantly higher than non-newly diagnosed subgroup (2.05±0.56 vs. 1.10±0.45, P<0.01). The expression of microRNA-182 had a positive correlation with anti-ds-DNA antibody and SLEDAI (r=0.466, P<0.01 and r=0.442, P<0.01, respectively), and ROC suggested that the value of microRNA-182 in diagnosis for SLE was high [AUC: 0.94 (95% CI 0.91–0.98)]. Conclusion: microRNA-182 is a potential biomarker in diagnosis for SLE.